Find clinical trials for Adenocarcinoma in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma

Cancer

Pancreatic Cancer

Colorectal Cancer

Stomach Cancer

Esophageal Cancer

Prostatic Cancer

Adenocarcinoma trials near Budapest, Budapest, HUN:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting

Gastric Cancer, Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: Ramucirumab

Drug: Paclitaxel

Phase 3

Daiichi Sankyo

Budapest, Hungary and 155 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

Phase 3

Arcus Biosciences

Budapest, Hungary and 203 other locations

Locations recently updated

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling

Non-small Cell Lung Cancer

Drug: Pemetrexed

Drug: Rilvegostomig

Phase 3

AstraZeneca

Budapest, Hungary and 214 other locations

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

cancer in the pancreas.Adult participants with metastatic pancreatic adenocarcinoma will receive Test Product (TP) and Reference Product (RP...

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma

Drug: Irinotecan liposome injection

Drug: Folinic Acid

Phase 1

Ipsen

Budapest, Hungary and 35 other locations

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric Cancer

Drug: Capecitabine

Drug: Trastuzumab deruxtecan

Phase 3

AstraZeneca

Budapest, Hungary and 204 other locations

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting

Fallopian Tube Adenocarcinoma

Fallopian Tube Serous Adenocarcinoma

Drug: Paclitaxel

Biological: Placebo

Phase 3

CanariaBio

Budapest, Hungary and 148 other locations

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Other: Placebo

Drug: Nivolumab

Phase 3

Amgen

Budapest, Hungary and 348 other locations

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas...

Enrolling

MSI-H/dMMR Gastroesophageal-junction Cancer

MSI-H/dMMR Gastric Cancer

Drug: S095029

Drug: pembrolizumab 200 mg (KEYTRUDA ®)

Phase 1, Phase 2

Servier

Budapest, Hungary and 39 other locations

Locations recently updated

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Enrolling

Solid Tumors

Drug: Bemarituzumab

Phase 1, Phase 2

Amgen

Budapest, Hungary and 114 other locations

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-s...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Gefitinib 250 mg

Drug: Gefitinib-matching placebo 250 mg

Phase 3

Yuhan

Törökbálint, Hungary and 79 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Budapest, Budapest

Related conditions:

Adenocarcinoma trials near Budapest, Budapest, HUN:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Find clinical trials for Adenocarcinoma in Budapest, Budapest